SPOTLIGHT -
Urine test shows utility in prostate biopsy decision-making in Black men
“This data emphasizes the importance of utilizing the EPI test for risk assessment of high-risk prostate cancer in [African American] men," concluded the authors.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
Vibegron improves overactive bladder symptoms in pharmacologically treated BPH
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
Dr. Murphy on increasing diversity in cancer clinical trials
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Real-world data show high darolutamide use for mHSPC in community urology setting
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
Response to UGN-101 induction linked to favorable RFS in UTUC
UGN-101 showed efficacy in a broad population of patients with upper tract urothelial cancer and recurrence-free survival rates were high among patients who responded to UGN-101 induction therapy.
